Search Results - "Aguggini, S"

P157 MammaPrint 8-year follow up results in patients with early breast cancer from a single-center Italian cohort study by Fiorino, E., Giudici, F., Aguggini, S., Strina, C., Milani, M., Ziglioli, N., Dester, M., Barbieri, G., Alberio, M., Azzini, C., Ferrero, G., Ungari, M., Dreezen, C., Pronin, D., Generali, D.

Get full text

ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment by Ianza, A, Giudici, F, Pinello, C, Corona, SP, Strina, C, Bernocchi, O, Bortul, M, Milani, M, Sirico, M, Allevi, G, Aguggini, S, Cocconi, A, Azzini, C, Dester, M, Cervoni, V, Bottini, A, Cappelletti, M, Generali, D

“…A key tool for monitoring breast cancer patients under neoadjuvant treatment is the identification of reliable predictive markers. Ki67 has been identified as…”
Get full text

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer by Allevi, G, Strina, C, Andreis, D, Zanoni, V, Bazzola, L, Bonardi, S, Foroni, C, Milani, M, Cappelletti, M R, Gussago, F, Aguggini, S, Giardini, R, Martinotti, M, Fox, S B, Harris, A L, Bottini, A, Berruti, A, Generali, D

“…Background: The objective of this study was to determine the optimal scheduling of 2.5 mg daily letrozole in neoadjuvant breast cancer patients to obtain…”
Get full text

Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer by Bazzola, L, Foroni, C, Andreis, D, Zanoni, V, R Cappelletti, M, Allevi, G, Aguggini, S, Strina, C, Milani, M, Venturini, S, Ferrozzi, F, Giardini, R, Bertoni, R, Turley, H, Gatter, K, Petronini, P G, Fox, S B, Harris, A L, Martinotti, M, Berruti, A, Bottini, A, Reynolds, A R, Generali, D

“…Purpose: To assess whether the combination of letrozole, metronomic cyclophosphamide and sorafenib (LCS) is well tolerated and shows activity in primary breast…”
Get full text

Efficacy of extended aromatase inhibitors for hormone-receptor–positive breast cancer: A literature-based meta-analysis of randomized trials by Corona, S.P., Roviello, G., Strina, C., Milani, M., Madaro, S., Zanoni, D., Allevi, G., Aguggini, S., Cappelletti, M.R., Francaviglia, M., Azzini, C., Cocconi, A., Sirico, M., Bortul, M., Zanconati, F., Giudici, F., Rosellini, P., Meani, F., Pagani, O., Generali, D.

“…Endocrine treatment with Tamoxifen and aromatase inhibitors (AIs) is a staple in the management of hormone receptor positive breast cancer (HR + BC). It has…”
Get full text

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer by Andreis, D, Bonardi, S, Allevi, G, Aguggini, S, Gussago, F, Milani, M, Strina, C, Spada, D, Ferrero, G, Ungari, M, Rocca, A, Nanni, O, Roviello, G, Berruti, A, Harris, A.L, Fox, S.B, Roviello, F, Polom, K, Bottini, A, Generali, D

“…Abstract Background Histological status of axillary lymph nodes is an important prognostic factor in patients receiving surgery for breast cancer (BC)…”
Get full text

Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1  and Relation to Clinical Response by Generali, D., Berruti, A., Cappelletti, M. R., Zanotti, L., Brugnoli, G., Forti, M., Bedussi, F., Vailati, M. E., Milani, M., Strina, C., Ardine, M., Aguggini, S., Allevi, G., Ferrero, G., Bertoni, R., Bottini, A., Harris, A. L., Fox, S. B.

Get full text

Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer by BOTTINI, A, BERRUTI, A, BETRI, E, BERTOLI, G, ALQUATI, P, DOGLIOTTI, L, BERSIGA, A, BRIZZI, M. P, BRUZZI, P, AGUGGINI, S, BRUNELLI, A, BOLSI, G, ALLEVI, G, GENERALI, D

“…The association between tumour shrinkage and reduction in kinetic cell activity after primary chemotherapy in human breast cancer is still a matter of…”
Get full text

Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis by Dovio, A., Generali, D., Tampellini, M., Berruti, A., Tedoldi, S., Torta, M., Bonardi, S., Tucci, M., Allevi, G., Aguggini, S., Bottini, A., Dogliotti, L., Angeli, A.

“…Summary The variability of serum osteoprotegerin (OPG) and soluble RANKL (sRANKL) along the 24-h cycle was assessed in 20 healthy women. No rhythmic variations…”
Get full text

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases by Generali, D, Dovio, A, Tampellini, M, Tucci, M, Tedoldi, S, Torta, M, Bonardi, S, Allevi, G, Aguggini, S, Milani, M, Harris, A L, Bottini, A, Dogliotti, L, Angeli, A, Berruti, A

“…Persistent circadian rhythm of bone turnover in bone metastatic breast cancer suggests greater skeletal retention of bisphosphonates if administered in the…”
Get full text

Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial by Bottini, A, Berruti, A, Brizzi, M P, Bersiga, A, Generali, D, Allevi, G, Aguggini, S, Bolsi, G, Bonardi, S, Tondelli, B, Vana, F, Tampellini, M, Alquati, P, Dogliotti, L

“…This study was designed to address whether simultaneous primary chemo-hormonal therapy provides additional activity compared with chemotherapy alone in breast…”
Get full text

Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer by BOTTINI, A, BERRUTI, A, ALQUATI, P, DOGLIOTTI, L, BRIZZI, M. P, BERSIGA, A, GENERALI, D, ALLEVI, G, AGUGGINI, S, BOLSI, G, BONARDI, S, BERTOLI, G

“…The purpose of this study was to evaluate whether tumour response to primary chemotherapy in human breast cancer is influenced by baseline haemoglobin (Hb)…”
Get full text

Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease by FIORENTINO, Carla, BERRUTI, Alfredo, ALQUATI, Palmiro, OLIVETTI, Lucio, DOGLIOTTI, Luigi, BOTTINI, Alberto, BODINI, Maria, BRIZZI, Maria Pia, BRUNELLI, Antonio, MARINI, Ugo, ALLEVI, Giovanni, AGUGGINI, Sergio, TIRA, Angela

“…The response to primary chemotherapy is an important prognostic factor in patients with non metastatic breast cancer. In this study we compared the assessment…”
Get full text

Cytotoxic and antiproliferative activity of the CMF regimen administered in association with tamoxifen as primary chemotherapy in breast cancer patients by Bottini, A, Berruti, A, Bersiga, A, Brunelli, A, Brizzi, M P, Di Marco, B, Cirillo, F, Tampellini, M, Bolsi, G, Aguggini, S, Betri, E, Filippini, L, Bertoli, A, Alquati, P, Dogliotti, L

“…Seventy six consecutive patients with T2-4, N0-1, M0 primary breast cancer (BC) received a median of 3 cycles of CMF (cyclophosphamide, methotrexate,…”
Get more information

Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease by Bottini, A, Berruti, A, Tampellini, M, Morrica, B, Brunelli, A, Gnocchi, E, Brizzi, M P, Aguggini, S, Fara, E, Alquati, P, Dogliotti, L

“…Serum levels of CA 15-3, mucinous-like cancer antigen, carcinoembryonic antigen, tissue polypeptide antigen and tissue polypeptide-specific antigen (TPS) have…”
Get more information

P3-07-25: Sentinel Lymph Node Mapping in Breast Cancer after Primary Chemotherapy by Bonardi, S, Andreis, D, Allevi, G, Aguggini, S, Milani, M, Generali, D, Bersiga, A, Brizzi, MP, Dogliotti, L, Berruti, A, Bottini, A

“…Abstract Background The High false negativity rate and the possible of interference of primary systemic treatment (PST) and biopsy on the lymphatic drainage in…”
Get full text

p53 but not bcl-2 Immunostaining Is Predictive of Poor Clinical Complete Response to Primary Chemotherapy in Breast Cancer Patients by BOTTINI, A, BERRUTI, A, FILIPPINI, L, BETRI, E, BERTOLI, G, ALQUATI, P, DOGLIOTTI, L, BERSIGA, A, BRIZZI, M. P, BRUNELLI, A, GORZEGNO, G, DIMARCO, B, AGUGGINI, S, BOLSI, G, CIRILLO, F

“…Preoperative chemotherapy administered to breast cancer (BC) patients is a model for studying in vivo the interaction between cytotoxic treatment and clinical…”
Get full text

The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load by Generali, Daniele, Berruti, Alfredo, Tampellini, Marco, Dovio, Andrea, Tedoldi, Sara, Bonardi, Simone, Tucci, Marcello, Allevi, Giovanni, Aguggini, Sergio, Milani, Manuela, Bottini, Alberto, Dogliotti, Luigi, Angeli, Alberto

“…Abstract Background Bone metastases are devastating events resulting in disruption of local bone remodeling processes. Physiological bone turnover has a…”
Get full text

Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy by BODINI, Maria, BERRUTI, Alfredo, AGUGGINI, Sergio, TAMPELLINI, Marco, ALQUATI, Palmiro, OLIVETTI, Lucio, DOGLIOTTI, Luigi, BOTTINI, Alberto, ALLEVI, Giovanni, FIORENTINO, Carla, BRIZZI, Maria Pia, BERSIGA, Alessandra, GENERALI, Daniele, VOLPI, Davide, MARINI, Ugo

“…To investigate whether magnetic resonance imaging (MRI) is superior to clinical palpation in the assessment of response of breast cancer to primary…”
Get full text

Changes in Microvessel Density As Assessed by CD34 Antibodies after Primary Chemotherapy in Human Breast Cancer by BOTTINI, Alberto, BERRUTI, Alfredo, SCARATTI, Lorena, BERTOLI, Giovanni, ALQUATI, Palmiro, DOGLIOTTI, Luigi, BERSIGA, Alessandra, BRIZZI, Maria Pia, ALLEVI, Giovanni, BOLSI, Giovanna, AGUGGINI, Sergio, BRUNELLI, Antonio, BETRI, Enrico, GENERALI, Daniele

“…Background: Several papers have shown that quantitationof tumor angiogenesis in primary breast cancer by counting blood vessels gives an independent assessment…”
Get full text